Understanding Wilson’s Disease
Wilson’s Disease is a rare genetic disorder characterized by excessive copper accumulation in the body, particularly in the liver and brain. This condition, caused by mutations in the ATP7B gene, leads to liver damage, neurological symptoms, and psychiatric disturbances. Without treatment, Wilson’s Disease can result in life-threatening organ damage and severe neurological impairment.
At MuriPhys, we are dedicated to supporting preclinical research aimed at developing therapies to manage copper accumulation and mitigate organ damage, driving advancements in Wilson’s Disease treatment.
Precision Drug Delivery for Wilson’s Disease
Targeted drug delivery plays a crucial role in reducing systemic copper overload and preventing organ deterioration. MuriPhys offers a variety of delivery methods tailored to Wilson’s Disease models, supporting effective therapeutic distribution:
- Oral Gavage (OG) – Mimics human oral drug administration, allowing for repeated dosing and systemic distribution.
- Intravenous (IV) Injection – Facilitates rapid delivery of therapeutic agents directly into the bloodstream.
- Intraperitoneal (IP) Injection: A systemic administration route, with absorption considered for the compound, formulation and study conditions.
- Subcutaneous (SC) Injection: Administration into subcutaneous tissue, with the exposure profile dependent on the test article and formulation.
These diverse delivery methods support a wide range of therapeutic approaches, from gene therapies to chelation treatments, tailored to preclinical models of Wilson’s Disease.
Behavioral and Metabolic Assays
Wilson’s Disease not only affects the liver but also leads to neurological and motor dysfunction. MuriPhys offers behavioral and metabolic assays designed to evaluate systemic effects and therapeutic efficacy:
- Rotarod and Balance Beam Tests – Assess motor coordination deficits resulting from copper-induced neurotoxicity.
- Open Field Test – Monitors general locomotion, anxiety, and exploratory behavior.
- Metabolic Chambers – Analyze systemic metabolic changes associated with liver dysfunction.
- Treadmill Testing – Evaluates endurance and muscular performance in models experiencing motor impairment.
These assays provide a comprehensive evaluation of disease progression, offering valuable insights into neurological and metabolic symptoms.
Imaging and Biomarker Analysis
Tracking disease progression and therapeutic response is vital in Wilson’s Disease research. MuriPhys utilizes advanced imaging technologies and partners with third party CROs for biomarker assessment to monitor copper accumulation and liver health:
- LI-COR Pearl Imager: Fluorescence imaging can contribute study-specific distribution or other suitably labeled readouts. Liver-function endpoints require appropriate biochemical or tissue measurements.
- Biochemical Analysis – Measures serum copper levels, ceruloplasmin, and liver enzymes to evaluate therapeutic impact.
- Histopathological Examination – Assesses liver fibrosis, cirrhosis, and neuronal damage.
These methods provide complementary biochemical, imaging and tissue information, with the sampling schedule and interpretation defined for the study.
Electrophysiology – Assessing Neurological Impact
Wilson’s Disease often results in neurological symptoms such as tremors, dystonia, and cognitive impairment. MuriPhys employs EEG and EMG technologies to monitor neural activity and neuromuscular function, enabling precise evaluation of neurodegeneration and therapeutic response.
Electrophysiological services include:
- EEG Recording – Tracks brain activity to identify neurological impairments.
- EMG Analysis – Measures muscle function and motor abnormalities linked to copper toxicity.
These tools are essential for characterizing the neurological impact of Wilson’s Disease and evaluating the efficacy of interventions aimed at reversing neural damage.
Why Choose MuriPhys for Wilson’s Disease Research?
Reach out to us to learn more about how MuriPhys can support your Wilson’s Disease research.